Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
December 5, 2024

Theratechnologies to license Ionis’ RNA-targeted therapies in Canada

Theratechnologies has entered into a licensing agreement with Ionis Pharmaceuticals to acquire exclusive Canadian rights for two investigational RNA-targeted medicines, olezarsen and donidalorsen.

Continue
The agreement involves Ionis’ investigational RNA-targeted medicines, olezarsen and donidalorsen. Credit: digitale.de on Unsplash.
December 4, 2024

Gilead and Tubulis sign ADC development deal for cancer treatment

The partnership leverages Tubulis' platforms to create an ADC with stability and reduced off-target toxicity. Credit: National Cancer Institute on Unsplash.
December 3, 2024

Japan MHLW grants orphan drug status to Renalys’ sparsentan for IgAN treatment

Sparsentan is intended to treat primary IgA nephropathy, a prominent cause of kidney failure. Credit: Robina Weermeijer on Unsplash.

Contracts

August 9, 2024

Bavarian Nordic secures $156.8m US vaccine deal

The vaccine is marketed under various brand names. Credit: Mathurin NAPOLY / matnapo on Unsplash.

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Deals

Deals July 15, 2024

Merck enhances ophthalmology portfolio with EyeBio acquisition

Pharmaceutical Business Review

Biocon signs licensing and supply deal for diabetes drug in Brazil

Q32 Bio concludes merger deal with Homology Medicines

Zuellig Pharma acquires Cialis and Alimta brands from Lilly

Popular

  1. Hong Kong regulator accepts Everest’s ulcerative colitis therapy NDA
  2. Dr. Reddy’s Laboratories introduces Toripalimab in India for nasopharyngeal carcinoma
  3. China’s NMPA grants marketing approval to Kelun-Biotech’s sac-TMT for TNBC treatment
  4. Valneva submits application seeking FDA approval for IXCHIQ for adolescent use
  5. FDA accepts Alnylam’s vutrisiran sNDA to treat ATTR-CM

PRESS RELEASES

Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site
Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site
Tosoh Bioscience – Separation & Purification Expands European Headquarters in Griesheim, Germany
Tosoh Bioscience – Separation & Purification Expands European Headquarters in Griesheim, Germany
BioSeparation Sustainable Biochromatography Forum ‒ Join Us in Vienna on 27 November 2024
BioSeparation Sustainable Biochromatography Forum ‒ Join Us in Vienna on 27 November 2024
Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency
Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency
Gerresheimer: EcoVadis Gold with Further Improved Score
Gerresheimer: EcoVadis Gold with Further Improved Score

Suppliers

Whitepapers

Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation